<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509701</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0385</org_study_id>
    <nct_id>NCT03509701</nct_id>
  </id_info>
  <brief_title>Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus</brief_title>
  <acronym>RCVS&amp;VZV</acronym>
  <official_title>Association Between Reversible Cerebral Vasoconstriction Syndrome and Herpes Zoster Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nowon Eulji Medical Center, Eulji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among patients with thunderclap headache who were admitted to the four participating
      hospitals, who has diffuse segmental vasoconstriction on CT angiography or MR angiography
      will be eligible for the study. Participants who meet the definition of RCVS will be enrolled
      as the case-patients and others will be enrolled as control-patients. The RCVS group will be
      defined when two or more neurologists agree by the clinical features and angiographic
      findings. The result of tests for varicella zoster virus titer will not be opened to
      neurologists until the end of the study. For case and control patients, tests for varicella
      zoster virus infection are (1) Pre-existing virological markers (ex. VZV-IgG, IgM, and VZV
      PCR in CSF or Skin lesion if present) (2) VZV-specific cell mediated immune response (CMI) at
      the time of admission and one month later (3) VZV in blood measured by quantitative test of
      viral load with real-time PCR and digital PCR for latent viral load (4) Quantitative test of
      viral load with real-time PCR in saliva at time of admission and one month later.
      Reactivation or infection of VZV of patients with RCVS and controls will be compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the previous pilot study, reactivation of VZV was confirmed in 63.6% of the patients as
      having RCVS by cell mediated immune response (CMI) test and 18.2% by Saliva PCR. None of
      patients who were simply stressed showed reactivation of VZV. Considering about 20% had false
      negative results in angiographic findings of RCVS, we set the effect size as 0.63 in group of
      subjects and 0.12 in group of controls. Using alpha values of 0.05 and beta values of 0.2, we
      calculated the target number of the study. If the ratio of cases to controls is 1:2, 9
      case-patients and 18 control-patients were needed and if the ratio is 1:3, 8 case-patients
      and 24 control-patients were needed. We expect to enroll 10 case-patients and 20 to 30
      control-patients within two years, considering the drop rate of 10~20%.

      Baseline clinical information regarding age, sex, smoking history and medical comorbidities
      including hypertension (treated, systolic blood pressure ≥140 mmHg or diastolic blood
      pressure ≥90 mmHg at discharge), diabetes (treated, fasting blood glucose ≥126 mg/d),
      hyperlipidemia (treated, total cholesterol level ≥200 mg/dl or low‐density lipoprotein level
      ≥140 mg/dl) and coronary artery disease will be collected on admission. Laboratory tests,
      including complete blood count, blood chemistry, c-reactive protein and erythrocyte sediment
      rate wil be performed. Images of brain MRI, MR angiography, CT angiography or digital
      substraction angiography will be gathered if present.

      Tests for VZV specific T-cell mediated immune response will be performed by VZV specific
      IFN-γ ELISPOT. Result will be shown as spot number per 10^6 PBMCs. On the day of blood sample
      collection, plasma will be isolated and freezed (-80℃). Peripheral mononuclear cells will be
      separated from the remaining blood samples and keep freezed (-190℃). Melt the frozen
      peripheral mononuclear cells and inoculate them on a plate (T-Track human IFN-γ, Lophius)
      with anti-human IFN-γ antibody and inoculate VZV lysate (Microbix) 50 ug/mL on them. After
      incubating 24 hours, the staining will be performed and the spot will be read in a automated
      ELISPOT reader (ELR07 reader system, Autoimmune Diagnostika GmbH).

      For statistical analysis, patients with thunderclap headache will divided into two groups
      according to the presence of RCVS. Among them, the rate of infection with varicella zoster
      virus will be compared and analyzed. Fisher's exact test, Mann-Whitney test, Pearson
      correlation will be performed. Also, logistic regression analysis will be used, and
      covariates will be adjusted if needed. Sensitivity and specificity of tests for reactivation
      of VZV and RCVS will be analyzed too.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infection or reactivation of varicella zoster virus (VZV)</measure>
    <time_frame>At the time of enrolled.</time_frame>
    <description>Compare prevalence of infection or reactivation of VZV in case-patients and control-patients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Reversible Cerebral Vasoconstriction Syndrome</condition>
  <condition>Varicella-zoster Virus Infection</condition>
  <arm_group>
    <arm_group_label>Subject (RCVS)</arm_group_label>
    <description>Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Varicella zoster virus specific T-cell mediated immune response</intervention_name>
    <description>Check VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay. Results are shown as spot number per 10^6 PBMCs. Lyse the frozen peripheral blood mononuclear cells and inoculate them on anti-human IFN-γ antibody attached plate (T-Track human IFN-γ, Lophius). Inoculate VZV lysate (Microbix) 50 ug/ml on them. After incubating for 24hours, stain will be performed and read the spot by an automated ELISPOT reader (ELR07 reader system, Autoimmune Diagnostika GmbH)</description>
    <arm_group_label>Subject (RCVS)</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Real time and digital polymerase chain reaction (PCR).</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who visited Asan medical center, Hanyang University Guri Hospital, Nowon Eulji
        Medical Center, or Kangbuk Samsung Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with thunderclap headache and suspicious of intracranial vascular lesion by
             computed tomographic angiography (CTA) or magnetic resonance angiography (MRA).

        Exclusion Criteria:

          -  Patients with life threatening medical condition

          -  Pregnant or scheduled for pregnancy

          -  Unwilling or unable to give informed consent

          -  Patients who confirmed vasculitis

          -  Patients with genetic disease for vascular disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Han Kim, MD.Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Han Kim, MD.PhD</last_name>
    <phone>82-2-3010-3305</phone>
    <email>kimsunghanmd@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyuk Sung Kwon, MD</last_name>
    <phone>82-31-560-2078</phone>
    <email>kwonhs@hanyang.ac.kr</email>
  </overall_contact_backup>
  <reference>
    <citation>Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, Calabrese LH. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011 Aug;68(8):1005-12. doi: 10.1001/archneurol.2011.68. Epub 2011 Apr 11.</citation>
    <PMID>21482916</PMID>
  </reference>
  <reference>
    <citation>Katz BS, Fugate JE, Ameriso SF, Pujol-Lereis VA, Mandrekar J, Flemming KD, Kallmes DF, Rabinstein AA. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014 Jan;71(1):68-73. doi: 10.1001/jamaneurol.2013.4639.</citation>
    <PMID>24190097</PMID>
  </reference>
  <reference>
    <citation>Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course. AJNR Am J Neuroradiol. 2015 Aug;36(8):1392-9. doi: 10.3174/ajnr.A4214. Epub 2015 Jan 15. Review.</citation>
    <PMID>25593203</PMID>
  </reference>
  <reference>
    <citation>Cuvinciuc V, Viguier A, Calviere L, Raposo N, Larrue V, Cognard C, Bonneville F. Isolated acute nontraumatic cortical subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2010 Sep;31(8):1355-62. doi: 10.3174/ajnr.A1986. Epub 2010 Jan 21. Review.</citation>
    <PMID>20093311</PMID>
  </reference>
  <reference>
    <citation>Kwon SU, Yun SC, Kim MC, Kim BJ, Lee SH, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Risk of stroke and transient ischaemic attack after herpes zoster. Clin Microbiol Infect. 2016 Jun;22(6):542-8. doi: 10.1016/j.cmi.2016.03.003. Epub 2016 Mar 16.</citation>
    <PMID>26992774</PMID>
  </reference>
  <reference>
    <citation>Kim MC, Yun SC, Lee HB, Lee PH, Lee SW, Choi SH, Kim YS, Woo JH, Kim SH, Kwon SU. Herpes Zoster Increases the Risk of Stroke and Myocardial Infarction. J Am Coll Cardiol. 2017 Jul 11;70(2):295-296. doi: 10.1016/j.jacc.2017.05.015.</citation>
    <PMID>28683973</PMID>
  </reference>
  <reference>
    <citation>Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006 Nov-Dec;27(10):2179-90.</citation>
    <PMID>17110690</PMID>
  </reference>
  <reference>
    <citation>Park SY, Kim JY, Kim JA, Kwon JS, Kim SM, Jeon NY, Kim MC, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Diagnostic Usefulness of Varicella-Zoster Virus Real-Time Polymerase Chain Reaction Analysis of DNA in Saliva and Plasma Specimens From Patients With Herpes Zoster. J Infect Dis. 2017 Dec 27;217(1):51-57. doi: 10.1093/infdis/jix508.</citation>
    <PMID>29029120</PMID>
  </reference>
  <reference>
    <citation>Yancy H, Lee-Iannotti JK, Schwedt TJ, Dodick DW. Reversible cerebral vasoconstriction syndrome. Headache. 2013 Mar;53(3):570-6. doi: 10.1111/head.12040.</citation>
    <PMID>23489219</PMID>
  </reference>
  <reference>
    <citation>Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012 Oct;11(10):906-17. doi: 10.1016/S1474-4422(12)70135-7. Review.</citation>
    <PMID>22995694</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Reversible cerebral vasoconstriction syndrome</keyword>
  <keyword>Herpes zoster</keyword>
  <keyword>Varicella-zoster virus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

